Skip to main content

Castle Biosciences Announces Availability of DecisionDx-EC Esophageal Cancer Tes

Castle Biosciences, a leading prognostic and molecular diagnostic company in Texas, has announced the release of a multi-biomarker test, DecisionDx-EC that helps in predicting the prognosis and resistance to chemo-radiation therapy in esophageal cancer patients before surgery.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino